{"id":6487,"date":"2026-02-20T13:52:25","date_gmt":"2026-02-20T13:52:25","guid":{"rendered":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/?p=6487"},"modified":"2026-03-12T13:40:19","modified_gmt":"2026-03-12T13:40:19","slug":"editors-column-february-2026","status":"publish","type":"post","link":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/volume-4-issue-1\/editors-column-february-2026\/","title":{"rendered":"Editor&#8217;s Column February 2026"},"content":{"rendered":"<p style=\"text-align: center;\"><a href=\"https:\/\/doi.org\/10.62055\/67479886Zp\">doi:10.62055\/67479886Zp<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>A couple of months ago, the American Academy of Ophthalmology released an update to its recommendations on how to screen for hydroxychloroquine retinal toxicity. It took me by surprise because I thought they had just recently made an update\u2026 how much could have changed? Then I started to read the article and realized it had been nearly a decade since their last update to the screening procedures. And plenty has changed. It was a very well-written and informative article, and I encourage everyone to <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41232611\/\">read it<\/a>. Then I realized this was the fourth article put out about hydroxychloroquine recommendations by this same group at the AAO since 2002 \u2013 and I remember reading about each one. Each time a paper came out, it changed the way we managed these patients in our eye clinic \u2013 overnight. The first recommendation in 2002 focused on 10-2 visual fields and ERGs. Then, nine years later, in 2011, it introduced the concepts of: a cumulative dose of 1000g, using \u201cideal weight\u201d in the 5mg\/kg calculation, and the novel concept of using SD-OCT to check the retina for damage. Five years later, in 2016, the AAO advised to move away from ideal weight, to focus more on SD-OCT and to start taking Fundus Autofluorescence (FAF) images and introduced the findings that patients with Asian ethnicity had a much larger diameter bullseye of maculopathy.<\/p>\n<p>Nine more years later, in 2025, the screening recommendations have changed again. The revision focuses on several parts. First, it directs the doctor\u2019s attention in the OCT scans to the Interdigitation Zone as the area to first show damage, followed by the Ellipsoid Zone and then the External Limiting Membrane. Second, it again draws our attention to the fact that the diameter of the bullseye can vary depending on the ethnicity of the patient. But the revision is careful to mention that \u201ca moderate percentage of patients from each group will show a contrary, or mixed pattern.\u201d I think, rather than trying to only look for toxicity in a certain area for a certain ethnicity, the best way to approach this is simply to know that toxicity can happen anywhere in the posterior pole; don\u2019t presume you know what diameter the bullseye will look like. Third, the revision focuses on the maximum of 5mg\/kg dosing recommendations and the danger of exceeding this dosing. Keep in mind that this means if a patient is taking a dose of 200mg BID, and if that patient is under 176lbs, then they are taking a higher dose than recommended.<\/p>\n<p>The revision ends by focusing on clinical tests, and this is where I think the biggest change in practice will come. It identifies SD-OCT and wide-angle FAF as primary tests, and visual fields and mf-ERGs as secondary, or confirmatory tests. It encourages the doctor to run the primary tests for every screening and to run a secondary test if the primary test shows any concern. Furthermore, the revision recommended 24-2C visual fields over the 10-2 visual fields, as a 10-2 is not wide enough to capture a larger-diameter bullseye.<\/p>\n<p>For years in my clinic, once a patient is on hydroxychloroquine for over five years, we recommended follow up visits twice a year. On one visit, we did a DFE with OCT and FAF, and on the next visit, we ran a 10-2 visual field. It\u2019ll be easy enough to switch to doing FAF using the 55<sup>o<\/sup> lens instead of the standard 30<sup>o<\/sup> lens. And switching from 10-2 to 24-2C is easy enough too. But I wonder if we need to be doing visual field testing at all? If the SD-OCT and widefield FAF are clear, will we skip the visual field in six months and just see the patient again in one year? What will you do in your practice?<\/p>\n<p>It\u2019s the sign of a powerful article \u2013 and the sign of a trusted institution \u2013 to be able to change the way doctors practice overnight. What are some articles that have changed practice overnight during your career? The DREAM study? A myopia or amblyopia study? I remember the rush to purchase pachymeters when the Ocular Hypertension Study came out. If your practice hasn\u2019t changed in several years, maybe it\u2019s because you aren\u2019t paying as close attention to the literature as you used to. Look to the articles in this issue as a potential source to change the way you practice. Kaitlyn Rooney presents an impressively deep review of the ocular complications of illicit drugs. Annmarie Craig and team show us that xerophthalmia doesn\u2019t just happen in underdeveloped countries, and describe what a clinician should check for in patients with the autistic spectrum disorder. Tyler Kitzman et al. write about an interesting case of MEWDS, which was found to be an epiphenomenon or secondary MEWDS. This was my first exposure to secondary MEWDS \u2013 be sure to check it out.<\/p>\n<p>Finally, this issue\u2019s featured article is a great case of Best disease by Zach Turple. It\u2019s a tour de force that explores inherited retinal disease with multimodal retinal imaging, electrodiagnostic testing and genetic sequencing. Read these articles and see if you don\u2019t find something that might revise the way you manage your next patient. After all, change is good. The opposite is stagnation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A couple of months ago, the American Academy of Ophthalmology released an update to its recommendations on how to screen for hydroxychloroquine&#8230;<\/p>\n","protected":false},"author":4,"featured_media":4297,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"105","_seopress_titles_title":"","_seopress_titles_desc":"A couple of months ago, the American Academy of Ophthalmology released an update to its recommendations on how to screen for hydroxychloroquine...","_seopress_robots_index":"","_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[65,105],"tags":[],"class_list":["post-6487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editors-column","category-volume-4-issue-1","et-has-post-format-content","et_post_format-et-post-format-standard"],"_links":{"self":[{"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/posts\/6487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/comments?post=6487"}],"version-history":[{"count":3,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/posts\/6487\/revisions"}],"predecessor-version":[{"id":6548,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/posts\/6487\/revisions\/6548"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/media\/4297"}],"wp:attachment":[{"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/media?parent=6487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/categories?post=6487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/journalofmedicaloptometry.com\/vol4issue2\/wp-json\/wp\/v2\/tags?post=6487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}